secwatch.observer — SEC 8-K summary
======================================

Issuer:     Liminatus Pharma, Inc. (LIMN)
CIK:        0001971387
Form:       8-K
Filed at:   2026-08-04T20:30:44+00:00
Accession:  0001104659-26-090423
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Liminatus Pharma shareholders approve reverse stock split authorization up to 1-for-50 at annual meeting
--------------------------------------------------------------------------------

- Elected Class I directors Nicholas Fernandez and Dr. Ji Yeon Baek with ~23.4M votes for each; broker non-votes 8.8M.
- Ratified WithumSmith+Brown as independent auditor for FY2026; 31.5M for, 0.89M against, 63k abstain.
- Approved reverse stock split authorization up to 1-for-50 at Board's discretion to meet Nasdaq minimum bid price; 30.1M for, 2.3M against.
- Quorum of 48.31% (32.4M shares) represented at the August 3, 2026 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926090423/0001104659-26-090423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971387/000110465926090423/tm2622207d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-090423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer